Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 339-345

  Li, Chun Wei ^a   Negendank, William G ^a   Padavic Shaller, Kristin A ^a   O'Dwyer, Peter J ^a   Murphy Boesch, Joseph ^a   Brown, Truman R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FLUORO BETA ALANINE; DRUG METABOLITE; FLUORINE 18; FLUOROURACIL;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 0029866540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol., 4: 597-602, 1993.
2. Presant, C. A., Wolf, W., Waluch, V., Wiseman, C., Kennedy, P., Blayney D., and Brechner, R. R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet, 343: 1184-1187, 1994.
3. Wolf, W., Albright, M. J., Silver, M. S., Weber, H., Reichardt, U., and Sauer, R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging, 5: 165-169, 1987.
4. Semmler, W., Bachert-Baumann, P., Guckel, F., Ermark, F., Schlag, P., Lorenz, W. J., and van Kaick, G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology, 174: 141-145, 1990.
5. 19F magnetic resonance spectroscopy. Br. J. Radiol., 63: 547-553, 1990.
6. Brown, T. R., Kincaid, B. M., and Ugurbil, K. NMR chemical shift imaging in three dimensions. Proc. Natl. Acad. Sci. USA, 79: 3523-3526, 1982.
7. Christensen, K. A., Grant, D. M., Schulman, E. M., and Walling, C. Optimal determination of relaxation times of Fourier transform nuclear magnetic resonance. Determination of spin-lattice relaxation times in chemically polarized species. J. Phys. Chem., 78: 1971-1978, 1974.
8. Gupta, R. K. A new look at the method of variable nutation angle for the measurement of spin-lattice relaxation times using Fourier transform NMR. J. Magn. Reson., 25: 231-235, 1977.
9. Staewen, R. S., Johnson, A. J., Ross, B. D., Parrish, T., Merkle, H., and Garwood, M. 3-D FLASH imaging using a single surface coil and a new adiabatic pulse, BIR-4. Invest. Radiol., 25: 559-567, 1990.
10. Bottomley, P. A., and Ouwerkerk, R. BIRP, an improved implementation of low-angle adiabatic (BIR-4) excitation pulses. J. Magn. Reson., 103: 242-244, 1993.
11. Liu, Z., Javaid, T , Hu, J., and Brown, T. R. CSI-Autoshim procedures for body and surface coil (Abstract). Proc Soc. Magn. Reson., 3: 1174, 1994.
12. Hu, J., Javaid, T., Arias-Mendoza, F., Liu, Z , MaNamara, R., and Brown, T. R. A fast, reliable automatic procedure for body and surface coil. J. Magn. Reson. (B), 108: 213-219, 1995.
13. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res., 48: 1680-1688, 1988.
14. 31P NMR spectroscopy. Magn. Reson. Med., 11: 1-21, 1989.
15. 31P magnetic resonance spectroscopy. NMR Biomed., 3: 1-22, 1990.
16. 31P spectroscopy: the definition of localized volumes, dealing with saturation and technique-dependence of quantitation. NMR Biomed., 2: 284-289, 1989.
17. Brown, T. R. Practical applications of chemical shift imaging. NMR Biomed., 5: 238-243, 1992.
18. 19F NMR. Br. J. Cancer, 50: 113-117, 1984.
19. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imaging, 12: 497-511, 1994.
20. Heggie, G. D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
21. Port, R. E., Bachert, P., and Semmler, W. Kinetic modeling of in vivo-nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors. Clin. Pharmacol., 49: 497-505, 1991.
22. 19F-NMR of tissues ex vivo (Abstract). Proc. Soc. Magn. Reson. Med., 10: 610, 1991.
23. Schalhorn, A., and Kuhl, M. Clinical pharmacokinetics of fluorouracil and folinic acid. Semin. Oncol., 19: 82-92, 1992.
24. Peters, G J., Lankelma, J., Kok, R. M., Noordhuis, P., van Groeningen, C. J., van der Wilt, C. L., Meyer, S., and Pinedo, H. M. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol., 31: 269-276, 1993.
25. Lautt, W. W. Hepatic vasculature: a conceptual review. Gastroenterology, 73: 1163-1169, 1977.
26. Stoyanova, R., Kuesel, A. C., and Brown, T. R. Application of principal component analysis for NMR spectral quantitation. J. Magn. Reson. (A), 115: 265-269, 1995.